SurgiQuest Reaches Over 100,000 Procedures Worldwide
AirSeal System used in over 100,000 Minimally Invasive Surgical procedures
Rapidly becoming an essential tool for robotic and laparoscopic surgery
MILFORD, Conn., Jan. 13, 2014 /PRNewswire/ -- SurgiQuest, Inc., a leading provider of innovative access technologies for minimally invasive surgery (MIS), today reported that surgeons have successfully used the AirSeal® System in more than 100,000 procedures worldwide.
SurgiQuest's patented AirSeal® Access System optimizes the laparoscopic environment and provides unparalleled stability in the abdominal cavity during MIS. Unlike conventional insufflation and trocar systems, the Company's breakthrough integrated platform ensures stable pneumoperitoneum, continuously evacuates smoke and plume when energized medical devices such as electro-cautery, laser or ultrasound are used, and provides valve-free access to the abdominal cavity during both robotic and laparoscopic surgical procedures. Recent clinical data suggests that use of the AirSeal system is associated with less post-operative pain, reduced pain medication use, and improved parameters for both intra-operative ventilation and hemodynamics.
"The AirSeal System has become my standard of care for use in robotic prostatectomy procedures," said Vipul Patel, M.D., the Medical Director of Florida Hospital's Global Robotics Institute and the world's most experienced robotic surgeon. "We are extremely pleased with the clinical benefits that it provides to our patients and with the improved efficiency we have seen in our robotic procedures since deploying the AirSeal System."
"Reliability in surgery is key. When it comes to creating a stable surgical environment, AirSeal truly sets itself apart from other technologies," said Arnold P. Advincula, who is the Vice Chair of Women's Health and Chief of Gynecology at Columbia University Medical Center in New York. "I won't perform a robotic procedure without it."
"We are absolutely thrilled by the tremendous growth in AirSeal adoption in both robotic and laparoscopic surgery across a wide range of surgical specialties," said Kurt Azarbarzin, the Founder and Chief Executive Officer of SurgiQuest. "The growing body of clinical evidence for the AirSeal System continues to demonstrate significant advantages for surgeons, anesthesiologists, operating room personnel, and, most importantly, patients."
SurgiQuest grew revenues over 130% in 2013 and is on track to grow by more than 100% in 2014. SurgiQuest expects to see approximately 115,000 AirSeal procedures performed in 2014 alone.
SurgiQuest, Inc. is a privately held venture-backed company, founded in May 2006. The Company develops, manufactures and markets innovative access technologies for minimally invasive surgery. SurgiQuest's patented AirSeal® System provides unprecedented access to the abdominal cavity during minimally invasive surgery ("MIS"). Unlike conventional insufflation and trocar systems, the Company's breakthrough integrated platform assures stable pneumoperitoneum, continuously evacuates smoke and plume when energized medical devices such as electrocautery, laser or ultrasound are used, and provides valve-free access to the abdominal cavity during both laparoscopic and robotic surgical procedures. Additional information about SurgiQuest products and clinical evidence can be found at www.surgiquest.com.
Senior Director of Marketing
SOURCE SurgiQuest, Inc.